CD4 and Hypertension: Excluding IVDUs from both samples resulted in an increase of 2 years in the median age, slightly higher prevalence of dyslipidemia and hypertension (72.0% and 36.2%, respectively) and better immunologic and virologic outcomes (CD4>500 cells/μL: 68.6%; viral load <50 copies/mL: 77.1%) in the 2013 sample with all the other measured parameters having negligible changes compared to those of the main analysis.